New RSV shot shows promise for vulnerable babies

NCT ID NCT06042049

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety and how the body processes two doses of nirsevimab, a medicine to prevent RSV, given 5 to 6 months apart. It included 33 Japanese infants up to 12 months old with heart or lung disease, weak immune systems, Down syndrome, or who were born early. Researchers checked for side effects and measured drug levels in the blood to ensure the medicine works well in these high-risk babies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LUNG DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease congenital heart disease Down syndrome immunodeficiency disease respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESPIRATORY SYNCYTIAL VIRUS INFECTIONS

Contacts and locations

Locations

Research Site

Bunkyō City, 113-8519, Japan
Research Site

Fuchu-shi, 183-8561, Japan
Research Site

Fukuoka, 813-0017, Japan
Research Site

Kitakyusyu-shi, 806-8501, Japan
Research Site

Kōtoku, 135-8577, Japan
Research Site

Kurume-shi, 830-0011, Japan
Research Site

Nagasaki, 852-8501, Japan
Research Site

Saitama-shi, 336-8522, Japan
Research Site

Yokohama, 232 8555, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.